Japan Tissue Engineering Co (TSE:7774) Cyclically Adjusted Revenue per Share: 円60.71 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:7774 Japan Tissue Engineering Co Ltd TSE:7774
55 GF Score
Price 円790.00
GF Value 円505.82
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Japan Tissue Engineering Co Cyclically Adjusted Revenue per Share?

Japan Tissue Engineering Co TSE:7774 -3.30% 55 Cyclically Adjusted Revenue per Share is 円60.71 as of Mar. 2026. GuruFocus rates TSE:7774 with a GF Score™ of 55/100 and a GF Value™ of 円505.82 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Japan Tissue Engineering Co's adjusted revenue per share for the three months ended in Mar. 2026 was 円16.576. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円60.71 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Japan Tissue Engineering Co was 15.30% per year. The lowest was 6.60% per year. And the median was 10.80% per year.

As of today (2026-09-12), Japan Tissue Engineering Co's current stock price is 円790.00. Japan Tissue Engineering Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円60.71. Japan Tissue Engineering Co's Cyclically Adjusted PS Ratio of today is 13.01.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Japan Tissue Engineering Co was 70.15. The lowest was 7.77. And the median was 13.13.


Japan Tissue Engineering Co  (TSE:7774) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Japan Tissue Engineering Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=790.00/60.71
=13.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Japan Tissue Engineering Co was 70.15. The lowest was 7.77. And the median was 13.13.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Japan Tissue Engineering Co Cyclically Adjusted Revenue per Share Related Terms


Japan Tissue Engineering Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Japan Tissue Engineering Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Japan Tissue Engineering Co Cyclically Adjusted Revenue per Share Chart

Japan Tissue Engineering Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.30 50.12 54.63 0.00 60.71

Japan Tissue Engineering Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.52 59.20 59.93 60.71 0.00

TSE:7774 vs VRTX, REGN, MRNA: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Japan Tissue Engineering Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Japan Tissue Engineering Co Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Japan Tissue Engineering Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Japan Tissue Engineering Co's Cyclically Adjusted PS Ratio falls into.


TSE:7774
55GF Score
Japan Tissue Engineering Co Ltd TSE:7774
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Japan Tissue Engineering Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Japan Tissue Engineering Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=16.576/112.7000*112.7000
=16.576

Current CPI (Mar. 2026) = 112.7000.

Japan Tissue Engineering Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 11.687 97.900 13.454
201606 8.886 98.100 10.208
201609 10.008 98.000 11.509
201612 9.546 98.400 10.933
201703 24.163 98.100 27.759
201706 12.504 98.500 14.307
201709 14.340 98.800 16.357
201712 12.778 99.400 14.488
201803 16.314 99.200 18.534
201806 10.445 99.200 11.866
201809 14.752 99.900 16.642
201812 12.665 99.700 14.316
201903 20.201 99.700 22.835
201906 10.663 99.800 12.041
201909 13.554 100.100 15.260
201912 12.843 100.500 14.402
202003 19.819 100.300 22.269
202006 9.304 99.900 10.496
202009 13.274 99.900 14.975
202012 11.485 99.300 13.035
202103 21.529 99.900 24.287
202106 11.779 99.500 13.342
202109 12.371 100.100 13.928
202112 15.139 100.100 17.045
202203 12.495 101.100 13.929
202206 10.409 101.800 11.524
202209 13.530 103.100 14.790
202212 11.609 104.100 12.568
202303 14.500 104.400 15.653
202306 16.305 105.200 17.467
202309 14.392 106.200 15.273
202312 13.274 106.800 14.007
202403 17.940 107.200 18.860
202406 10.894 108.200 11.347
202409 17.718 108.900 18.336
202503 0.000 111.100 0.000
202506 10.501 111.700 10.595
202509 14.093 112.000 14.181
202512 12.581 113.000 12.548
202603 16.576 112.700 16.576

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円60.71 mean?
Japan Tissue Engineering Co (TSE:7774) has a Cyclically Adjusted Revenue per Share of 円60.71 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Japan Tissue Engineering Co and its competitors.
Is Japan Tissue Engineering Co's Cyclically Adjusted Revenue per Share too high?
Japan Tissue Engineering Co's current Cyclically Adjusted Revenue per Share is 円60.71. Overall, Japan Tissue Engineering Co has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Japan Tissue Engineering Co's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Japan Tissue Engineering Co's Cyclically Adjusted Revenue per Share of 円60.71 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Japan Tissue Engineering Co and its competitors. Japan Tissue Engineering Co's current Cyclically Adjusted Revenue per Share is 円60.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Tissue Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Japan Tissue Engineering Co (TSE:7774) is currently considered Significantly Overvalued. The stock's GF Value™ is 円505.82, compared to a current price of 円790.00 — trading 56.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円60.71. Japan Tissue Engineering Co's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Japan Tissue Engineering Co (TSE:7774), the current Cyclically Adjusted Revenue per Share is 円60.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Japan Tissue Engineering Co (TSE:7774) Overvalued in 2026?

Based on GuruFocus' analysis, Japan Tissue Engineering Co stock appears to be overvalued. The current stock price of 円790.00 is trading 56.2% above its estimated GF Value™ of 円505.82. GuruFocus considers Japan Tissue Engineering Co to be Significantly Overvalued.

Key valuation signals for TSE:7774:

  • Cyclically Adjusted Revenue per Share: 円60.71
  • GF Value™: 円505.82 vs. price of 円790.00 (56.2% above fair value)
  • GF Score™: 55/100 with 3 warning signs

No single metric tells the full story. See the TSE:7774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Japan Tissue Engineering Co Business Description

Address 6-209-1 Miyakitadori, Gamagori, Aichi, JPN, 443-0022
Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.
55GF Score

Get the complete analysis for TSE:7774

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円790.00
Price
円505.82
GF Value